Advertisement

Topics

Genentech Release: FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (Vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation

20:00 EDT 6 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Genentech Release: FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (Vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation

NEXT ARTICLE

More From BioPortfolio on "Genentech Release: FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (Vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation"

Quick Search
Advertisement